首页> 美国卫生研究院文献>BMC Infectious Diseases >Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis
【2h】

Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis

机译:在一个耐多药结核病发病率较低的国家结核分枝杆菌分离株在表型上易受利福平的影响而出现有争议的rpoB突变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundAccurate drug susceptibility testing (DST) of Mycobacterium tuberculosis in clinical specimens and culture isolates to first-line drugs is crucial for diagnosis and management of multidrug-resistant tuberculosis (MDR-TB). Resistance of M. tuberculosis to rifampicin is mainly due to mutations in hot-spot region of rpoB gene (HSR-rpoB). The prevalence of disputed (generally missed by rapid phenotypic DST methods) rpoB mutations, which mainly include L511P, D516Y, H526N, H526L, H526S, and L533P in HSR-rpoB and I572F in cluster II region of rpoB gene, is largely unknown. This study determined the occurrence of all disputed mutations in HSR-rpoB and at rpoB codon 572 in M. tuberculosis strains phenotypically susceptible to rifampicin in Kuwait.
机译:背景对一线药物的临床标本和培养分离物进行准确的结核分枝杆菌药敏试验(DST)对于诊断和管理耐多药结核病(MDR-TB)至关重要。结核分枝杆菌对利福平的耐药性主要归因于rpoB基因(HSR-rpoB)热点区域的突变。在rpoB基因簇II区的HSR-rpoB和I572F中主要存在L511P,D516Y,H526N,H526L,H526S和L533P以及I572F的有争议的rpoB突变(通常被快速的表型DST方法所遗漏)的流行率很高。这项研究确定了在表型上对科威特利福平敏感的结核分枝杆菌菌株中HSR-rpoB和rpoB 572位密码子所有有争议的突变的发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号